SG11202003111SA - Antibodies targeting cd137 and methods of use thereof - Google Patents

Antibodies targeting cd137 and methods of use thereof

Info

Publication number
SG11202003111SA
SG11202003111SA SG11202003111SA SG11202003111SA SG11202003111SA SG 11202003111S A SG11202003111S A SG 11202003111SA SG 11202003111S A SG11202003111S A SG 11202003111SA SG 11202003111S A SG11202003111S A SG 11202003111SA SG 11202003111S A SG11202003111S A SG 11202003111SA
Authority
SG
Singapore
Prior art keywords
methods
antibodies targeting
targeting
antibodies
Prior art date
Application number
SG11202003111SA
Other languages
English (en)
Inventor
Tea Gunde
Matthias Brock
Christian Hess
Alexandre Simonin
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195780.6A external-priority patent/EP3470428A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of SG11202003111SA publication Critical patent/SG11202003111SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202003111SA 2017-10-10 2018-10-09 Antibodies targeting cd137 and methods of use thereof SG11202003111SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17195780.6A EP3470428A1 (en) 2017-10-10 2017-10-10 Antibodies targeting cd137 and methods of use thereof
EP18167092 2018-04-12
EP18180815 2018-06-29
PCT/EP2018/077514 WO2019072870A1 (en) 2017-10-10 2018-10-09 ANTIBODIES TARGETING CD137 AND METHODS OF USE

Publications (1)

Publication Number Publication Date
SG11202003111SA true SG11202003111SA (en) 2020-05-28

Family

ID=63834023

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003111SA SG11202003111SA (en) 2017-10-10 2018-10-09 Antibodies targeting cd137 and methods of use thereof

Country Status (10)

Country Link
US (1) US11578133B2 (enExample)
EP (1) EP3694880A1 (enExample)
JP (1) JP7438939B2 (enExample)
CN (1) CN111183159B (enExample)
AU (1) AU2018348431B2 (enExample)
CA (1) CA3075337A1 (enExample)
IL (1) IL273841B1 (enExample)
MA (1) MA50354A (enExample)
SG (1) SG11202003111SA (enExample)
WO (1) WO2019072870A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11365240B2 (en) * 2017-06-05 2022-06-21 Numab Therapeutics AG Anti-HSA antibodies
WO2019072868A1 (en) * 2017-10-10 2019-04-18 Numab Therapeutics AG MULTISPECIFIC ANTIBODIES
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
AU2020308463A1 (en) * 2019-06-26 2022-02-17 Ap Biosciences, Inc. Antibodies for T-cell activation
WO2021013142A1 (zh) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 抗4-1bb抗体、其抗原结合片段及双特异性抗体
CN117843786A (zh) * 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN115066440A (zh) * 2020-02-28 2022-09-16 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
WO2022189498A1 (en) * 2021-03-09 2022-09-15 Genmab A/S Multispecific binding agents against cd40 and cd137 in therapy
EP4395824A4 (en) * 2021-09-03 2025-10-22 Novarock Biotherapeutics Ltd BISPECIFIC AND TRISPECIFIC PD-L1, CD137 AND/OR TGF-BETA BINDING PROTEINS AND USES THEREOF
AU2024275787A1 (en) * 2023-05-19 2025-11-27 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
KR20000034847A (ko) 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
WO2004010947A2 (en) * 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
PH12020550156A1 (en) * 2010-09-09 2024-01-15 Pfizer 4-1bb binding molecules
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
CA2926153A1 (en) * 2013-10-25 2015-04-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016202457A1 (en) 2015-06-15 2016-12-22 Numab Ag Hetero-dimeric multi-specific antibody format
WO2019072868A1 (en) * 2017-10-10 2019-04-18 Numab Therapeutics AG MULTISPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
AU2018348431B2 (en) 2025-10-02
JP2020537520A (ja) 2020-12-24
CN111183159A (zh) 2020-05-19
CA3075337A1 (en) 2019-04-18
KR20200063153A (ko) 2020-06-04
US20200332015A1 (en) 2020-10-22
IL273841B1 (en) 2025-11-01
WO2019072870A1 (en) 2019-04-18
JP7438939B2 (ja) 2024-02-27
MA50354A (fr) 2020-08-19
US11578133B2 (en) 2023-02-14
AU2018348431A1 (en) 2020-03-12
EP3694880A1 (en) 2020-08-19
CN111183159B (zh) 2024-09-03
IL273841A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
IL273841A (en) Antibodies directed against cd137 and methods of their use
IL290809B1 (en) Tau-protein targeted protacs and related methods of use
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
SI3618863T1 (sl) Protitelesa proti tigitu in načini uporabe njih
IL259495A (en) Antibodies and methods for using them
SG11202000387YA (en) B7-h4 antibodies and methods of use thereof
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL259681A (en) New antibodies against claudin and methods of using them
IL260019A (en) Antibodies targeting cd32b and methods of using them
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
IL323510A (en) Antibodies directed against 1PDL and methods of use thereof
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
ZA202002144B (en) Antibodies and methods of use
IL281767A (en) CD137-directed antibodies and methods of using them
HK40031493A (en) Antibodies targeting cd137 and methods of use thereof
HK40056395A (en) Antibodies targeting cd137 and methods of use thereof
HK40031482A (en) Antibodies targeting pdl1 and methods of use thereof